inPractice® - Treatment Options

Hepatic Disease in HIV-Infected Patients

Author: Mark S. Sulkowski, MD (More Info)
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 9/4/18 (What's New)

Summary

Highly active DAA regimens are now recommended as part of preferred or alternative regimens for HCV/HIV-coinfected patients by the AASLD/IDSA (Management Guidelines)^{[AASLD-IDSA HCV]}and EASL (Management Guidelines)^{[EASL HCV]} guidance panels

Genotype 1 HCV/HIV Coinfection

AASLD/IDSA and EASL guidance panels recommend highly active DAA regimens for genotype 1 HCV/HIV–coinfected patients (Management Guidelines)^{[AASLD-IDSA HCV]}(Management Guidelines)^{[EASL HCV]}

Non–Genotype 1 HCV

AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for genotype 2-6 HCV infection in HCV/HIV-coinfected patients (Table 10) (Management Guidelines)^{[AASLD-IDSA HCV]}

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatic Complications, Special Populations, Treatment Complications, Viral Hepatitis Coinfection